Search

Your search keyword '"Costanzo, Antonio"' showing total 1,295 results

Search Constraints

Start Over You searched for: Author "Costanzo, Antonio" Remove constraint Author: "Costanzo, Antonio" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
1,295 results on '"Costanzo, Antonio"'

Search Results

2. Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

4. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

9. Embedding Resilience to Climate Change and Natural Hazards in Smart Services

14. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

19. A Noise Mitigation Approach for VLC Systems

20. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

25. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

26. Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

29. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.

30. Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study.

31. Splenic trauma: WSES classification and guidelines for adult and pediatric patients

32. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

33. Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals

34. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

35. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study

36. Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

38. Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features

39. Gender influence and bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life multicenter experience

40. 51042 Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma

41. Global disparities in surgeons’ workloads, academic engagement and rest periods: the on-calL shIft fOr geNEral SurgeonS (LIONESS) study

42. Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study

43. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

44. Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

45. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

46. Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

47. Health-Related Quality of Life in Psoriasis: Literature Review.

48. Seismic survey in urban area: the activities of the EMERSITO INGV emergency group in Ancona (Italy) following the 2022 MW 5.5 Costa Marchigiana-Pesarese earthquake.

49. Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features.

50. Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study.

Catalog

Books, media, physical & digital resources